IGC Pharma (IGC) Total Non-Current Liabilities (2011 - 2026)
IGC Pharma (IGC) posted quarterly Total Non-Current Liabilities of $191000.0 for Q1 2026, up 19.38% year-over-year from $160000.0 in Q1 2025, and up 43.61% quarter-over-quarter from $133000.0 in Q4 2025.
IGC Pharma (IGC) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Total Non-Current Liabilities for 16 consecutive years, with $191000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 19.38% year-over-year to $191000.0; the TTM figure through Mar 2026 stood at $191000.0 (up 19.38% YoY), while the FY2026 annual figure was $191000.0, up 19.38% from the prior year.
- Total Non-Current Liabilities grew to $191000.0 in Q1 2026 per IGC's latest filing, from $133000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $501000.0 in Q1 2022 and bottomed at $133000.0 in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged $273941.2 across 5 years, with a median of $241000.0 in 2024.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities tumbled 40.0% — and 2026, when it rose 19.38%.
- IGC Pharma's Total Non-Current Liabilities stood at $397000.0 in 2022, then slumped by 31.99% to $270000.0 in 2023, then sank by 40.0% to $162000.0 in 2024, then fell by 17.9% to $133000.0 in 2025, then soared by 43.61% to $191000.0 in 2026.
- Business Quant data shows IGC's Total Non-Current Liabilities at $191000.0 in Q1 2026, $133000.0 in Q4 2025, and $137000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | 191,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 191,000.00 |
| Dec 31, 2025 | 133,000.00 |
| Sep 30, 2025 | 137,000.00 |
| Jun 30, 2025 | 140,000.00 |
| Mar 31, 2025 | 160,000.00 |
| Dec 31, 2024 | 162,000.00 |
| Sep 30, 2024 | 190,000.00 |
| Jun 30, 2024 | 225,000.00 |
| Mar 31, 2024 | 241,000.00 |
| Dec 31, 2023 | 270,000.00 |
| Sep 30, 2023 | 302,000.00 |
| Jun 30, 2023 | 340,000.00 |
| Mar 31, 2023 | 369,000.00 |
| Dec 31, 2022 | 397,000.00 |
| Sep 30, 2022 | 432,000.00 |
| Jun 30, 2022 | 467,000.00 |
| Mar 31, 2022 | 501,000.00 |
| Dec 31, 2021 | 534,000.00 |
| Sep 30, 2021 | 565,000.00 |
| Jun 30, 2021 | 595,000.00 |